<DOC>
	<DOCNO>NCT01625091</DOCNO>
	<brief_summary>The primary objective study evaluate whether intervention involve medication naltrexone , reduce drink improve health outcome woman HIV infection hazardous drinking . Our central hypothesis , compare woman receive placebo ( sugar pill contain medicine ) , woman receive naltrexone decrease rate hazardous drinking , improve HIV medication adherence , less rapid disease progression , reduce sexual risk behavior . The study design involve 240 HIV-infected woman hazardous drinking , recruit HIV clinic , neighborhood referral Miami , Florida . Eligible woman receive either daily pill contain naltrexone ( 50mg ) identical-appearing placebo four month . All participant receive encouragement feedback related drinking regardless medication assignment . The study participant assess two , four seven month enrollment . The propose work innovative pharmacologic treatment alcohol evaluate HIV-infected woman . If hypothesis confirm , study finding would transform approach hazardous drinking within clinic serve HIV-infected woman .</brief_summary>
	<brief_title>Clinical Trial Reduce Drinking Women With HIV</brief_title>
	<detailed_description>The primary objective study evaluate acceptability effectiveness treatment program hazardous drinking , deliver within HIV-clinic outpatient setting , involve oral naltrexone . The central hypothesis woman participate treatment program decrease rate hazardous drink improved clinical behavioral health outcome associate hazardous drinking . The investigator formulate hypothesis base exist literature , preliminary data clinical experience . The investigator theorize woman receive alcohol treatment intervention less likely `` risk '' drink behavior 6-months enrollment , compare woman receive similar assessment formal treatment intervention . The investigator hypothesize 4-months enrollment , woman receive alcohol treatment intervention improve adherence HIV antiretroviral therapy , improve CD4 cell count , reduce HIV viral load , reduce risky sexual behavior , compare woman receive similar assessment formal intervention . The investigator recruit 240 woman one site Miami , Florida . Of 240 woman 120 receive naltrexone others receive placebo . Study participant take medication 4 month investigator follow 7 month . At baseline , 2 month , 4 month 7 month , investigator administer study questionnaire assess liver enzymes , CD4 count viral load . The investigator also follow month 1 3 reinforce medication intake ass possible side effect . New treatment option available , impact hazardous drinking yet evaluate among HIV-infected woman , many poor , minority , associate mental health substance abuse problem . Delivery therapeutic intervention must improve order reduce hazardous drink woman HIV/AIDS . The propose research significant therapy offer within HIV clinic setting potentially improve health population significantly undertreated . In addition determine effectiveness alcohol treatment intervention , investigator also identify key barrier facilitator associate adherence pharmacologic treatment alcohol woman hazardous drinking . The finding directly affect type quality care hazardous drinking subset HIV-infected individual inform primary secondary prevention effort .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>( must meet follow ) : Hazardous drinking , average , precede 4 week . Defined binge drinking ( 4 drink per occasion least twice monthly ) and/or high total weekly consumption ( &gt; 7 drink per week ) . Age 18 Female HIV infection ( documented medical record blood test result test do study ) Able understand comply study procedure provide write consent . Exclusion criterion : ( follow ) : Contraindications treatment naltrexone Current physiologic opiate dependence Current daily prescription opioid medication Positive urine drug test opioids Allergic naltrexone Significantly abnormal baseline liver enzyme ( AST ALT &gt; =5 time upper normal ) , evidence acute hepatitis , receive hemodialysis renal failure Currently pregnant Currently take alcohol treatment medication ( disulfiram , topiramate , naltrexone , acamprosate ) . Currently unable provide mail address reliable contact information , plan move area within next 7 month Unable communicate English Spanish Research coordinator assessment participant comprehend study consent procedure ( e.g . participant appear intoxicated , answer question nonsensible manner ) Has current prognosis less one year live ( e.g . Hospice , metastatic cancer ) Currently take antiviral treatment hepatitis C infection ( interferon ribavirin ) Has unique health condition , specifically list , exclude participant discussion Dr. Cook , Dr. Espinoza , perhaps also participant 's primary HIV physician ( example unexpected abnormal laboratory result turn baseline screen metabolic panel ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>woman</keyword>
	<keyword>drinking</keyword>
	<keyword>Naltrexone</keyword>
</DOC>